AKT1 and ovarian cancer: In line with our result, genetic or pharmacological inhibition of USP14 led to reduced phosphorylation of Akt and/or Erk1/2 in hepatocellular carcinoma cells and monocytic leukemia cells.25, 26 Moreover, inhibition of PI3K/AKT and ERK1/2 signaling pathways could enhance cisplatin sensitivity in urothelial bladder cancer cells and ovarian cancer cells, respectively.27, 28